Beth Faiman, PhD, MSN, APRN-BC, AOCN, BMTCN, FAAN, Cleveland Clinic, Cleveland, OH, outlines the aims and features of the Cleveland Clinic Survivor Care Program Model in patients with multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

David Vesole, MD, PhD, is the director of the Myeloma Program at MedStar Georgetown University Hospital. He is also a member of the blood and marrow transplant team. To see all of the questions Dr. Vesole answers, click on “show more” below. Clicking on the question takes you directly to his answer.

To make an appointment with Dr. Vesole, please call 202-295-0520 or visit MedStarGeorgetown.org/Myeloma

0:00 Meet Dr. David Vesole

3:37 What is multiple myeloma or myeloma?

4:11 Are there different types of myeloma?

5:03 How do you determine the genetic makeup of the myeloma?

5:41 How does the genetic makeup of the myeloma determine the treatment?

6:47 Is there a cure for myeloma?

8:05 How did I get multiple myeloma or myeloma?

8:38 If somebody in my family has multiple myeloma should I be screened for it?

8:54 What are the treatments for myeloma?

10:04 What are some of the latest therapies for multiple myeloma?

11:20 What are the symptoms of myeloma?

11:43 How long will I live with this disease?

12:47 What are the stages of multiple myeloma?

13:30 How does stem cell transplant work as a treatment for multiple myeloma?

15:54 Is there a difference between stem cell transplant and bone marrow transplant?

16:31 How will I feel after the chemo and stem cell transplant?

17:52 When will I know if the stem cell transplant has worked?

18:19 Is a stem cell transplant a cure for myeloma?

18:34 How long can I expect my remission to last?

19:37 Are there any ethnic groups who are at higher risk for getting multiple myeloma?

20:14 What is C.R.A.B.?

20:37 What is the relationship between MedStar Georgetown and Hackensack University Medical Center?

Images from teaching files of Afshin Karimi, MD, PhD, JD, Assistant Clinical Professor of Radiology, University of California Medical Center, San Diego. Images uploaded by Michael Jin.

Nikhil Munshi, MD presents the diagnosis and risk assessment in multiple myeloma at Dana-Farber's 202 Multiple Myeloma Patient Symposium.

G protein-coupled receptor family C group 5 member D (GPRC5D) has limited expression in normal human tissue but is highly expressed on malignant plasma cells, making it a promising immunotherapy target for patients with multiple myeloma. Talquetamab is a T-cell bispecific antibody targeting both GPRC5D and CD3 receptors. Ajai Chari, MD, Mount Sinai School of Medicine, New York, NY, outlines findings of MonumenTAL-1 (NCT03399799/NCT04634552), a Phase I/II trial of talquetamab in patients with relapsed/ refractory (R/R) multiple myeloma. 143 patients were treated at 0.4 mg/kg weekly. The median age of patients was 67 years, and all had received a median of 5 prior lines of treatment. Results showed that responses were durable and deepened over time, with the overall response rate (ORR) being 73%. Median time to complete response (CR) was 2.1 months, while the median progression-free survival (PFS) was 7.5 months. The most common adverse events (AEs) were CRS, dysgeusia and anemia; skin-related AEs and nail disorders were also observed in a number of patients. Cytopenias, including neutropenia and thrombocytopenia were also recorded but were generally limited to the first few cycles. Overall, talquetamab demonstrated robust efficacy and manageable safety in patients with heavily pretreated R/R multiple myeloma. This press briefing took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.